CRL vs. PFE: Charles River Laboratories vs. Pfizer Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while PFE is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Pfizer (PFE) is defensive at 0.35 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Charles River Laboratories (CRL) at 1.27% and Pfizer (PFE) at 4.47% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Pfizer (PFE) at 6.34% retains a top-quartile share of revenue as profit, ahead of Charles River Laboratories (CRL) at 1.01%, which keeps about the industry-typical share.

Both Charles River Laboratories (CRL) at 23.42% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Charles River Laboratories (CRL) at -0.85% and Pfizer (PFE) at -1.65% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Pfizer (PFE) at -3.55% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Both Charles River Laboratories (CRL) at 1.41 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Charles River Laboratories (CRL) at 0.87 and Pfizer (PFE) at 0.71 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Charles River Laboratories (CRL) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics